Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CANCERDIP

Financiado

Cerrado

The use of Methylated DNA Immunoprecipitation MeDIP in cancer for better clinica...

The use of Methylated DNA Immunoprecipitation MeDIP in cancer for better clinical management Aberrant DNA methylation is the most common molecular lesion of the cancer cell. Neither gene mutation nor cytogenetic abnormalities are as common in human tumours as DNA methylation alterations. The stability of our genome and co... ver más

30/06/2011

FUNDACIO INSTITUT...

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

FUNDACIO INSTITUT D?INVESTIGACIO BIOMEDICA DE... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 16M€

Fecha límite participación Sin fecha límite de participación.

Ver 7 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2011-06-30 No tenemos la información de la convocatoria

0% 76% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

7 Participantes

FUNDACIO INSTITUT D?INVESTIG...

0.00€ | Lider

MPG

N.D. | Participante

DIAGENODE

N.D. | Participante

Proyectos interesantes

SAF2012-31138

Medical Technol...

Data Science

70K€ Cerrado

CANCER EPIGENETICS

Medical Technol...

Data Science

100K€ Cerrado

DNAMETHYLOOPMCL

Medical Technol...

Data Science

166K€ Cerrado

methDRE

Medical Technol...

Data Science

100K€ Cerrado

BFU2011-27658

Medical Technol...

Data Science

128K€ Cerrado

PRIME

Medical Technol...

Data Science

2M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

FUNDACIO INSTITUT D?INVESTIGACIO BIOMEDICA DE... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 16M€

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Aberrant DNA methylation is the most common molecular lesion of the cancer cell. Neither gene mutation nor cytogenetic abnormalities are as common in human tumours as DNA methylation alterations. The stability of our genome and correct gene expression is maintained to a great extent thanks to a perfectly preestablished pattern of DNA methylation and histone modifications. In cancer this idealistic scenario breaks down due to an interesting phenomenon whereby the regulatory regions (CpG islands) of certain tumour suppressor genes become hypermethylated, inactivating the gene as a consequence, whilst a wave of hypomethylation occurs in the genome. Indeed, CpG island promoter hypermethylation has a tumour-type-specific pattern, where each gene tends to be methylated in the cancer cells driven from a particular tissue, but not from others. It is also widely accepted that the multiprotein complex associated with the methylated DNA is also crucially involved in the repression of gene expression. Another aspect crucial for the interest of epigenetics in cancer is that promoter hypermethylation of the CpG island of tumours suppressor genes occurs early in tumorigenesis. Furthermore, it has been extensively reported that CpG promoter hypermethylation can be used as predictor of cancer behaviour and a predictor of response to treatment. This characteristic makes promoter hypermethylation combined with the epigenetic associated proteins profile, a potential biomarker for early detection of cancer and for the individualization of cancer treatment. We are going to use a novel technique based in chromatin immunoprecipitation, the Methylated DNA Immunoprecipitation (MeDIP) technique that will easily permit us to obtain an epigenomic profile which will be used to personalize cancer treatment and facilitate tumour diagnosis, prognosis and monitoring.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores